Caroline Morbieu

Caroline Morbieu

Auto-generated profile, based on publicly available information

Caroline Morbieu

Coordinated Department of Internal Medicine, AP-HP Paris Nord-Louis-Mourier Hospital, Colombes, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2016 in Critical Care
Verified
Journal Article
Open access
PDF file
GVGuillaume Voiriot
Guillaume Voiriot
BVBenoit Visseaux
Benoit Visseaux
JCJohana Cohen
Johana Cohen
LNLiem Binh Luong Nguyen
Liem Binh Luong Nguyen
MNMathilde Neuville
Mathilde Neuville
jean-francois timsitjean-francois timsit
jean-francois timsit
Multiplex polymerase chain reaction (mPCR) enables recovery of viruses from airways of patients with community-acquired pneumonia (CAP), although their clinical impact remains uncertain. Among consecutive adult patients who had undergone a mPCR within 72 hours following their admission to one intensive care unit (ICU), we retrospectively included those with a final diagnosis of CAP. Four etiology groups were clustered: bacterial, viral, mixed (viral-bacterial) and no etiology. A composite criterion of complicated course (hospital death or mechanical ventilation > 7 days) was used. A subgroup analysis compared patients with bacterial and viral-bacterial CAP matched on the bacterial pathogens. Among 174 patients (132 men [76 %], age 63 [53–75] years, SAPSII 38 [27;55], median PSI score 106 [78;130]), bacterial, viral, mixed and no etiology groups gathered 46 (26 %), 53 (31 %), 45 (26 %) and 30 (17 %) patients, respectively. Virus-infected patients displayed a high creatine kinase serum level, a low platelet count, and a trend toward more frequent alveolar-interstitial infiltrates. A complicated course was more frequent in the mixed group (31/45, 69 %), as compared to bacterial (18/46, 39 %), viral (15/53, 28 %) and no etiology (12/30, 40 %) groups (p < 0.01). In multivariate analysis, the mixed (viral-bacterial) infection was independently associated with complicated course (reference: bacterial pneumonia; OR, 3.58; CI 95 %, 1.16–11; p = 0.03). The subgroup analysis of bacteria-matched patients confirmed these findings. Viral-bacterial coinfection during severe CAP in adults is associated with an impaired presentation and a complicated course.

22 December 2023 in Science Immunology
Verified
Journal Article
Open access
PBPaul Bastard
Paul Bastard
SVSara E. Vazquez
Sara E. Vazquez
JLJamin Liu
Jamin Liu
MLMatthew Laurie
Matthew Laurie
CWChung Yu Wang
Chung Yu Wang
JDJoseph L. DeRisi
Joseph L. DeRisi
Life-threatening “breakthrough” cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; their contribution to hypoxemic breakthrough cases in vaccinated people is unknown. We studied a cohort of 48 individuals (aged 20 to 86 years) who received two doses of a messenger RNA (mRNA) vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Ab levels to the vaccine, neutralization of the virus, and auto-Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal Ab response to the vaccine. Among them, 10 (24%) had auto-Abs neutralizing type I IFNs (aged 43 to 86 years). Eight of these 10 patients had auto-Abs neutralizing both IFN-α2 and IFN-ω, whereas two neutralized IFN-ω only. No patient neutralized IFN-β. Seven neutralized type I IFNs at 10 ng/ml and three at 100 pg/ml only. Seven patients neutralized SARS-CoV-2 D614G and Delta efficiently, whereas one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only type I IFNs at 100 pg/ml neutralized both D614G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating Abs capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a notable proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population.

14 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MMMatthieu Mahévas
Matthieu Mahévas
VTViet-Thi Tran
Viet-Thi Tran
MRMathilde Roumier
Mathilde Roumier
ACAmélie Chabrol
Amélie Chabrol
RPRomain Paule
Romain Paule
NCNathalie Costedoat-Chalumeau
Nathalie Costedoat-Chalumeau
Background: Treatments are urgently needed to prevent respiratory failure and deaths from coronavirus disease 2019 (COVID-19). Hydroxychloroquine (HCQ) has received worldwide attention because of positive results from small studies. Methods: We used data collected from routine care of all adults in 4 French hospitals with documented SARS-CoV-2 pneumonia and requiring oxygen ≥ 2 L/min to emulate a target trial aimed at assessing the effectiveness of HCQ at 600 mg/day. The composite primary endpoint was transfer to intensive care unit (ICU) within 7 days from inclusion and/or death from any cause. Analyses were adjusted for confounding factors by inverse probability of treatment weighting. Results: This study included 181 patients with SARS-CoV-2 pneumonia; 84 received HCQ within 48 hours of admission (HCQ group) and 97 did not (no-HCQ group). Initial severity was well balanced between the groups. In the weighted analysis, 20.2% patients in the HCQ group were transferred to the ICU or died within 7 days vs 22.1% in the no-HCQ group (16 vs 21 events, relative risk [RR] 0.91, 95% CI 0.47–1.80). In the HCQ group, 2.8% of the patients died within 7 days vs 4.6% in the no-HCQ group (3 vs 4 events, RR 0.61, 95% CI 0.13–2.89), and 27.4% and 24.1%, respectively, developed acute respiratory distress syndrome within 7 days (24 vs 23 events, RR 1.14, 95% CI 0.65–2.00). Eight patients receiving HCQ (9.5%) experienced electrocardiogram modifications requiring HCQ discontinuation. Interpretation: These results do not support the use of HCQ in patients hospitalised for documented SARS-CoV-2-positive hypoxic pneumonia.

15 May 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
THThông Hua-Huy
Thông Hua-Huy
CLChristine Lorut
Christine Lorut
FAFrederique AUBOURG
Frederique AUBOURG
CMCaroline Morbieu
Caroline Morbieu
JMJonathan Marey
Jonathan Marey
Anh Tuan Dinh-XuanAnh Tuan Dinh-Xuan
Anh Tuan Dinh-Xuan

9 July 2018 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
CMCaroline Morbieu
Caroline Morbieu
FBFrancesco Brunetti
Francesco Brunetti
LBLaurence Baranès
Laurence Baranès
LLLaetitia Languille
Laetitia Languille
NLNicolas Limal
Nicolas Limal
MMMatthieu Mahévas
Matthieu Mahévas

Verified
Journal Article
Open access
PDF file
THThông Hua-Huy
Thông Hua-Huy
SGSven Günther
Sven Günther
CLChristine Lorut
Christine Lorut
MSMarielle Subileau
Marielle Subileau
FAFrederique AUBOURG
Frederique AUBOURG
Anh Tuan Dinh-XuanAnh Tuan Dinh-Xuan
Anh Tuan Dinh-Xuan
Pulmonary sequelae as assessed by pulmonary function tests (PFTs) are often reported in patients infected by SARS-CoV-2 during the post-COVID-19 period. Little is known, however, about the status of pulmonary inflammation during clinical recovery after patients’ discharge from the hospitals. We prospectively measured PFTs coupled with the exhaled nitric oxide (NO) stemming from the proximal airways (FeNO) and the distal lung (CaNO) in 169 consecutive patients with varying degrees of the severity of COVID-19 six weeks to one year after acute infection by SARS-CoV-2. The proportions of patients with abnormal PFTs, defined as the presence of either obstructive/restrictive patterns or impaired lung gas transfer, or both, increased with the severity of the initial lung disease (15, 30, and 52% in patients with mild, moderate, and severe COVID-19). FeNO values remained within normal ranges and did not differ between the three groups of patients. CaNO, however, was significantly higher in patients with severe or critical COVID-19, compared with patients with milder forms of the disease. There was also an inverse relationship between CaNO and DLCO. We conclude that the residual inflammation of the distal lung is still present in the post-COVID-19 follow-up period, in particular, in those patients with an initially severe form of COVID-19. This long-lasting alveolar inflammation might contribute to the long-term development of pulmonary fibrosis and warrants the regular monitoring of exhaled NO together with PFTs in patients with COVID-19.